Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

26/03/2014 New companies in the UAB Research Park 18/03/2014 The public-private partnership ESTEVE-UAB is bearing fruit 11/03/2014 Barcelona ranked fourth place among the most attractive European cities for investors 24/02/2014 Zero2infinity offers sightseeing flights in the stratosphere 18/02/2014 Students from Harvard visited the Barcelona Synchrotron Park and ALBA 11/02/2014 Applications of the Alba synchrotron in the materials and chemistry industries
42 43 44 45 46 47 48 49